pentoxiphylline

PreclinicalSmall molecule

IInstitute of Liver and Biliary Sciences, India

pentoxiphylline is one of 51 small molecule programs targeting Hepatitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HepatitisActive, not recruiting

Non-Alcoholic SteatohepatitisActive, not recruiting

High Risk PatientsWithdrawn

HepatitisPreclinical

Active, not recruiting

Non-Alcoholic SteatohepatitisPreclinical

Active, not recruiting

High Risk PatientsPreclinical

Withdrawn

Competition

Competitive Landscape

39 competitors in Hepatitis

#DrugCompanyPhaseTrials

Medrol

Pfizer

Approved

2 2

Byetta

AstraZeneca

Approved

1 3

Viread

Sovaldi

Tyzeka

Glucophage

3 7

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

1 8

Singulair

OOrganon and Co

Approved

1 9

Epivir

GGlaxo Dba Glaxosmithkline

Approved

—10

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

High Risk Patients1 trial

Renal Effect of Pentoxyphylline in High Risk Patients Undergoing Angiography

Withdrawn·MMeir Medical Center·N/A·NCT01144091

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for pentoxiphylline. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — pentoxiphylline compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for pentoxiphylline. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institute of Liver and Biliary Sciences, India company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IInstitute of Liver and Biliary Sciences, India

pentoxiphylline

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

High Risk Patients1 trial

Dialysis Patients1 trial

Non-Alcoholic Steatohepatitis1 trial

Hepatitis1 trial

References

Drug Info

Quick Facts

Related News